<DOC>
	<DOCNO>NCT00170794</DOCNO>
	<brief_summary>The purpose study determine extent cyclosporine microemulsion dose reduction require maintain stable renal function maintenance cardiac transplant recipient , initiation everolimus .</brief_summary>
	<brief_title>Renal Safety Everolimus Addition Cyclosporine Microemulsion Cardiac Transplant Recipients .</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Male female cardiac transplant recipient , 1870 year old , establish cardiac allograft vasculopathy risk develop cardiac allograft vasculopathy . Patients 12 month posttransplant receive cyclosporine microemulsionbased immunosuppressive regimen with/without azathioprine /mycophenolate mofetil , with/without steroid . Patients need stable renal function calculate GFR exceed 40 ml/min ( Nankivell ) . Patients without biopsyproven acute rejection ≥ grade 2 , within 12 month prior study entry . Females childbearing potential must negative serum pregnancy test within 7 day prior enrollment . Effective contraception must use trial 4 week follow discontinuation study medication , even history infertility . Patients willing able participate full course study write informed consent obtain . Patients recipients multiple solid organ transplant . Patients calculate GFR le 40 ml/min . Patients biopsyproven acute rejection episode ≥ 2 within 12 month prior study entry . Patients receive investigational drug within 4 week prior study entry . Patients currently treat sirolimus history prior therapy hypersensitivity drug similar everolimus . Patient platelet count &lt; 50,000/mm3 white blood cell count ≤ 2,500/mm3 hemoglobin value &lt; 10 g/dL . Presence severe hypercholesterolemia ( ≥ 9.1 mmol/L ) hypertriglyceridemia ( ≥ 8.55 mmol/L ) . Patient NYHA class IV heart failure , leave ventricular ejection fraction &lt; 30 % . Patients lifethreatening cardiac allograft vasculopathy and/or graft dysfunction ( life expectancy 1 year ) . Patients severe systemic infection . Patients know HBsAg HCV positive hepatitis , HIV positive . Serology result obtain within 6 month prior study entry acceptable . If result obtain prior study entry , sample must retain later analysis . This stored sample destroy end study . Patients past ( within last 5 year ) present malignancy nonmelanotic skin cancer . Existence comorbid condition likely result death prior study completion Symptoms significant mental illness , opinion investigator may interfere patient 's ability comply protocol . History drug alcohol abuse within 1 year baseline . Inability cooperate communicate investigator . Female patient childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cardiac transplantation , everolimus , cyclosporine microemulsion , GFR</keyword>
</DOC>